-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HG+01mfU1l0yEzxjfOv+lCy/Wg/VCeFqd0P7nd6CafR+CoRlwnweunsHc2XkT6/F 8+aQCWMPA/it0OqY5x+JpA== 0000947871-99-000125.txt : 19990331 0000947871-99-000125.hdr.sgml : 19990331 ACCESSION NUMBER: 0000947871-99-000125 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990330 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AQUILA BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0000704292 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 043307818 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-35873 FILM NUMBER: 99578659 BUSINESS ADDRESS: STREET 1: 175 CROSSING BLVD STREET 2: BIOTECHNOLOGY RESEARCH PARK CITY: FRAMINGHAM STATE: MA ZIP: 01605 BUSINESS PHONE: 5087975777 MAIL ADDRESS: STREET 1: 365 PLANTATION STREET CITY: WORCESTER STATE: MA ZIP: 01605 FORMER COMPANY: FORMER CONFORMED NAME: CAMBRIDGE BIOTECH CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: CAMBRIDGE BIOSCIENCE CORP DATE OF NAME CHANGE: 19901116 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ORBIMED ADVISERS INC /CT CENTRAL INDEX KEY: 0001033248 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 41 MADISON AVENUE 40TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 2126850800 FORMER COMPANY: FORMER CONFORMED NAME: MEHTA & ISALY ASSET MANAGEMENT INC DATE OF NAME CHANGE: 19970212 SC 13G 1 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AQUILA BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 03839F107 (CUSIP Number) February 4, 1998 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1 (b) |x| Rule 13d-1 (c) |_| Rule 13d-1 (d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 03839F107 (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person OrbiMed Advisors LLC ---------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of Group (See Instructions) [ ] (a) [ ] (b) ---------------------------------------------------------------------- (3) SEC Use Only ---------------------------------------------------------------------- (4) Citizenship or Place of Organization Delaware ---------------------------------------------------------------------- Number of (5) Sole Voting Power 0 Shares Beneficially ------------------------------------------------------------- Owned by (6) Shared Voting Power 523,000 Each - Reporting ------------------------------------------------------------- Person (7) Sole Dispositive Power 0 With ------------------------------------------------------------- (8) Shared Dispositive Power 523,000 ---------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 523,000 ---------------------------------------------------------------------- (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ---------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 7.5% ---------------------------------------------------------------------- (12) Type of Reporting Person (See Instructions) CO ---------------------------------------------------------------------- CUSIP No. 03839F107 (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Caduceus Capital Trust ---------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of Group (See Instructions) [ ] (a) [ ] (b) ---------------------------------------------------------------------- (3) SEC Use Only ---------------------------------------------------------------------- (4) Citizenship or Place of Organization Bermuda ---------------------------------------------------------------------- Number of (5) Sole Voting Power 0 Shares Beneficially ------------------------------------------------------------- Owned by (6) Shared Voting Power 523,000 Each - Reporting ------------------------------------------------------------- Person (7) Sole Dispositive Power 0 With ------------------------------------------------------------- (8) Shared Dispositive Power 523,000 ---------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 523,000 ---------------------------------------------------------------------- (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ---------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 7.5% ---------------------------------------------------------------------- (12) Type of Reporting Person (See Instructions) OO ---------------------------------------------------------------------- CUSIP No. 03839F107 (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Finsbury Worldwide Pharmaceutical Trust ---------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of Group (See Instructions) [ ] (a) [ ] (b) ---------------------------------------------------------------------- (3) SEC Use Only ---------------------------------------------------------------------- (4) Citizenship or Place of Organization United Kingdom ---------------------------------------------------------------------- Number of (5) Sole Voting Power 0 Shares Beneficially ------------------------------------------------------------- Owned by (6) Shared Voting Power 523,000 Each - Reporting ------------------------------------------------------------- Person (7) Sole Dispositive Power 0 With ------------------------------------------------------------- (8) Shared Dispositive Power 523,000 ---------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 523,000 ---------------------------------------------------------------------- (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ---------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 7.5% ---------------------------------------------------------------------- (12) Type of Reporting Person (See Instructions) OO ---------------------------------------------------------------------- Item 1. Issuer (a) Aquila Biopharmaceuticals, Inc. (b) 175 Crossing Boulevard, Framingham, Masssachusetts 01702 Item 2. Persons Filing (a) Name of Persons Filing: OrbiMed Advisors LLC Finsbury Worldwide Pharmaceutical Trust Caduceus Trust (b) Address of Principal Offices: c/o OrbiMed Advisors Inc. 767 Third Avenue, 6th Floor New York, New York 10010 (c) Citizenship: Please refer to Item 4 on each cover sheet for each filing person (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 03839F107 Item 3. Not Applicable Item 4. Ownership Please see Items 5, 6, 7, 8, 9, and 11 for each cover sheet for each filing entity. Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: March 29, 1999 ORBIMED ADVISORS LLC By: /s/ Samuel D. Isaly ---------------------------- Name: Samuel D. Isaly Title: Managing Member CADUCEUS CAPITAL TRUST By: /s/ Deborah O'Donnel ---------------------------- Name: Deborah O'Donnel Title: Secretary FINSBURY WORLDWIDE PHARMACEUTICAL TRUST By: /s/ Samuel D. Isaly ---------------------------- Name: Samuel D. Isaly Title: Director -----END PRIVACY-ENHANCED MESSAGE-----